Abortion pill fight thrust into spotlight as midterms heat up

A federal court has thrust the issue of abortion back into the national spotlight, just months before the midterm elections.  

Voter anger about abortion rights after the Supreme Court overturned Roe v. Wade in 2022 helped propel Democrats to a series of midterm victories that year. 

But when then-Vice President Kamala Harris lost the White House despite prioritizing abortion messaging, the issue took a back seat to affordability, the economy and cost-of-living concerns. 

Now, the Supreme Court is again faced with a potential nationwide ban on mail-order mifepristone, creating an opening for abortion rights advocates and a political headache for the Trump administration and Republicans in tough races.

Access to mifepristone, the first in the two-drug regimen commonly used in medication abortion, has emerged as one of the most significant battles over abortion in the years since Roe v. Wade was overturned in Dobbs v. Jackson Women’s Health Organization. 

But the Trump administration has stayed largely silent on the politically fraught topic, frustrating the GOP’s anti-abortion base. 

A conservative federal appeals court on Friday severely curtailed abortion access when it prohibited mifepristone from being prescribed without an in-person doctor visit. Supreme Court Justice Samuel Alito then temporarily restored mail-order access— for one week. 

“This is the biggest setback nationally for abortion access since Dobbs,” said Mini Timmaraju, president of the national abortion rights group Reproductive Freedom for All. “We’re relieved temporarily, but we are not out of the woods.” 

The fight over abortion has continued in many states even as it has lost some potency on the national level. Reproductive rights advocates are hopeful they can use the lawsuit to help elevate the issue back into the consciousness of voters nationwide.

“This is certainly the most significant development in the courts on abortion since........

© The Hill